Key discussion points:
- Are GLP-1s still dominating the top 10? What does that mean for the leading companies in 2025?
- Where are the most valuable pipeline products emerging?
- Which therapy areas and new drugs are likely to drive growth?
- Are we finally set for a return to dealmaking?
- And what impact could the new Trump administration have on deals and the wider pharma outlook in 2025?